Cas no 3106-18-1 (5'-Uridylic acid, monosodium salt)
5'-Uridylic acid, monosodium salt Chemical and Physical Properties
Names and Identifiers
-
- 5'-Uridylic acid, monosodium salt
- uridine-5'-monophosphate sodium
- Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate
- Sodium((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methylhydrogenphosphate
- sodium [(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
- SCHEMBL3090916
- Uridine 5'-monophosphate disodium salt
- 3106-18-1
- C9H12N2NaO9P
- Sodium 5'-O-(hydroxyphosphinato)uridine
- C74595
- CHEMBL1627073
- AS-62133
- AKOS025405218
- CID 23676677
- sodium;[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
- SODIUM [(2R,3S,4R,5R)-5-(2,4-DIOXO-3H-PYRIMIDIN-1-YL)-3,4-DIHYDROXYOXOLAN-2-YL]METHYL HYDROGEN PHOSPHATE
- Uridine 5'-Monophosphate Sodium Salt
- 5'-Uridylic acid, sodium salt (1:1)
-
- MDL： N/A
- Inchi： 1S/C9H13N2O9P.Na/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18);/q;+1/p-1/t4-,6-,7-,8-;/m1./s1
- InChI Key： WHRWYTJLFJEXDD-IAIGYFSYSA-M
- SMILES： P(=O)(O)([O-])OC[C@@H]1[C@H]([C@H]([C@H](N2C=CC(NC2=O)=O)O1)O)O.[Na+]
Computed Properties
- Exact Mass: 346.01781124g/mol
- Monoisotopic Mass: 346.01781124g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 9
- Heavy Atom Count: 22
- Rotatable Bond Count: 4
- Complexity: 529
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 4
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 169?2
5'-Uridylic acid, monosodium salt Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H332-H335
- Warning Statement： P261-P280-P305+P351+P338
- Storage Condition：Inert atmosphere,Room Temperature(BD305293)
5'-Uridylic acid, monosodium salt Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-FA261-200mg |
5'-Uridylic acid, monosodium salt |
3106-18-1 | 98% | 200mg |
128.0CNY | 2021-08-04 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-FA261-50mg |
5'-Uridylic acid, monosodium salt |
3106-18-1 | 98% | 50mg |
55.0CNY | 2021-08-04 | |
| Chemenu | CM252108-1g |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 98% | 1g |
$*** | 2023-03-29 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-HK640-250mg |
5'-Uridylic acid, monosodium salt |
3106-18-1 | 98% | 250mg |
101CNY | 2021-05-08 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1226259-5g |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 98% | 5g |
￥1188.00 | 2024-08-02 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | S33320-250mg |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 250mg |
￥146.0 | 2021-09-07 | ||
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | S33320-1g |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 1g |
￥356.0 | 2021-09-07 | ||
| Ambeed | A132664-250mg |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 98% | 250mg |
$15.0 | 2023-02-28 | |
| Ambeed | A132664-1g |
Sodium ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate |
3106-18-1 | 98% | 1g |
$37.0 | 2023-02-28 | |
| Aaron | AR0032QM-50mg |
5'-Uridylic acid, sodium salt (1:1) |
3106-18-1 | 95% | 50mg |
$12.00 | 2025-01-21 |
5'-Uridylic acid, monosodium salt Related Literature
-
Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
-
J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
-
Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
-
Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
Additional information on 5'-Uridylic acid, monosodium salt
Introduction to 5'-Uridylic acid, monosodium salt (CAS No. 3106-18-1)
5'-Uridylic acid, monosodium salt, with the chemical formula C?H?N?O?Na, is a significant compound in the field of nucleoside chemistry and has garnered considerable attention due to its diverse applications in pharmaceuticals, biotechnology, and research. This compound, identified by its CAS number 3106-18-1, is a sodium salt derivative of uridylic acid, a crucial nucleotide component found in RNA. Its unique structural and chemical properties make it a valuable intermediate in the synthesis of nucleoside analogs and other bioactive molecules.
The 5'-Uridylic acid, monosodium salt is particularly notable for its role in the development of antiviral drugs, where it serves as a precursor for modified nucleosides that exhibit enhanced pharmacological activity. Recent advancements in medicinal chemistry have highlighted its potential in designing inhibitors for viral polymerases, particularly those targeting RNA-dependent RNA polymerases. These inhibitors are critical in the fight against RNA viruses, including influenza and coronaviruses.
In the realm of biotechnology, 5'-Uridylic acid, monosodium salt is widely utilized in the synthesis of modified nucleotides that mimic natural nucleotides but possess altered biological activities. Such modifications have led to the development of novel therapeutic agents with improved efficacy and reduced side effects. For instance, studies have demonstrated its utility in creating antisense oligonucleotides (ASOs) that can specifically target and regulate gene expression. ASOs are being explored for treating a variety of genetic disorders, including cystic fibrosis and Huntington's disease.
Moreover, 5'-Uridylic acid, monosodium salt has found applications in the field of mRNA therapeutics. The mRNA vaccine technology, which gained prominence during the COVID-19 pandemic, relies heavily on nucleoside analogs to stabilize and enhance the efficacy of mRNA molecules. The compound’s ability to interact with RNA structures makes it an ideal candidate for improving mRNA delivery systems and reducing degradation rates. This has opened up new avenues for developing effective vaccines and treatments for various infectious diseases.
Recent research has also explored the role of 5'-Uridylic acid, monosodium salt in modulating cellular processes beyond its traditional applications. Studies indicate that this compound can influence RNA splicing and processing, which are essential for generating functional proteins. By interacting with spliceosomes and other RNA-binding proteins, 5'-Uridylic acid, monosodium salt may help regulate gene expression patterns relevant to cancer and neurodegenerative diseases. These findings underscore its potential as a therapeutic agent in precision medicine.
The synthesis of 5'-Uridylic acid, monosodium salt involves well-established chemical pathways that ensure high purity and yield. Industrial-scale production typically employs enzymatic or chemical methods to convert uridine into uridylic acid and subsequently into its sodium salt form. Advances in synthetic methodologies have enabled more efficient and sustainable production processes, reducing environmental impact while maintaining product quality.
In conclusion, 5'-Uridylic acid, monosodium salt (CAS No. 3106-18-1) is a versatile compound with far-reaching implications in pharmaceuticals and biotechnology. Its role in antiviral drug development, gene regulation therapies, mRNA therapeutics, and cellular process modulation highlights its significance as a key intermediate in modern medicine. As research continues to uncover new applications for this compound, its importance is expected to grow further.
3106-18-1 (5'-Uridylic acid, monosodium salt) Related Products
- 3387-36-8(Uridine 5′-monophosphate disodium salt)
- 35170-03-7(Uridine 3’-Monophosphate Disodium Salt)
- 27416-86-0(5'-Uridylic acid,homopolymer)
- 58-98-0(Uridine 5'-(trihydrogendiphosphate))
- 28086-43-3([5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid)
- 365-07-1(Thymidine-5'-monophosphoric acid)
- 10003-94-8(Uridine5'-(pentahydrogen tetraphosphate) (9CI))
- 18354-06-8(1-b-D-Arabinofuranosyluracil 5'-Monophosphate)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
